Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

CD19-targeted CAR T Cells （JWCAR029） for Primary Refractory Diffuse Large B Cell Lymphoma, Phase Ⅰ,Open-label,Single-arm,Muticenter Study

NCT04812691 is registered in ClinicalTrials.gov with Shanghai Ming Ju Biotechnology Co., Ltd. as lead sponsor.

NCT NCT04812691
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04812691 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
CD19-targeted CAR T Cells （JWCAR029） for Primary Refractory Diffuse Large B Cell Lymphoma, Phase Ⅰ,Open-label,Single-arm,Muticenter Study
Lead sponsor
Shanghai Ming Ju Biotechnology Co., Ltd.
Phase
Phase 1
Overall status
Completed
Start date
July 10, 2020
Completion date
April 25, 2023
Enrollment
12 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b cell lymphoma